Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Chief Scientific Officer | July 06, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monte Rosa Therapeutics, Inc.
Report date July 06, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,845 |
Ending reported balance
After 2026-07-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-06 · Exercise / conversion · Acquired 6,000 · Balance 73,845 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Row 2 · 2026-07-06 · Sale · Disposed 5,600 · Balance 68,245 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.97 to $23.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-07-06 · Sale · Disposed 400 · Balance 67,845 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2031-04-12 | Direct | 197,290 |
Reported balance
After 2026-07-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-06 · Exercise / conversion · Disposed 6,000 · Balance 197,290 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F3: The shares underlying this option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.97 to $23.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The shares underlying this option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 7, 2026 20:41 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001193125-26-297558 · ownership.xml · derivative · entry 4 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,290 Underlying: Common Stock · 6,000 shares Expires 2031-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 20:41 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 400 | $24.13 | $9,652.00 |
DisclosureSEC source: 0001193125-26-297558 · ownership.xml · nonDerivative · entry 3 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,845 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 20:41 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 5,600 | $23.25 | $130,197.20 |
DisclosureSEC source: 0001193125-26-297558 · ownership.xml · nonDerivative · entry 2 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,245 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.97 to $23.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 20:41 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionCommon Stock | 6,000 | $6.14 | $36,840.00 |
DisclosureSEC source: 0001193125-26-297558 · ownership.xml · nonDerivative · entry 1 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001193125-26-282736 · ownership.xml · derivative · entry 3 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,290 Underlying: Common Stock · 3,000 shares Expires 2031-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 3,000 | $20.00 | $60,000.00 |
DisclosureSEC source: 0001193125-26-282736 · ownership.xml · nonDerivative · entry 2 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,845 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionCommon Stock | 3,000 | $6.14 | $18,420.00 |
DisclosureSEC source: 0001193125-26-282736 · ownership.xml · nonDerivative · entry 1 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001193125-26-275805 · ownership.xml · derivative · entry 3 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,290 Underlying: Common Stock · 3,000 shares Expires 2031-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 3,000 | $19.00 | $57,000.00 |
DisclosureSEC source: 0001193125-26-275805 · ownership.xml · nonDerivative · entry 2 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,845 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionCommon Stock | 3,000 | $6.14 | $18,420.00 |
DisclosureSEC source: 0001193125-26-275805 · ownership.xml · nonDerivative · entry 1 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001193125-26-251395 · ownership.xml · derivative · entry 3 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,290 Underlying: Common Stock · 6,000 shares Expires 2031-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 6,000 | $19.87 | $119,220.00 |
DisclosureSEC source: 0001193125-26-251395 · ownership.xml · nonDerivative · entry 2 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,845 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $20.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 20:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionCommon Stock | 6,000 | $6.14 | $36,840.00 |
DisclosureSEC source: 0001193125-26-251395 · ownership.xml · nonDerivative · entry 1 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 21:04 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 3,155 | $15.17 | $47,861.35 |
DisclosureSEC source: 0001193125-26-002385 · ownership.xml · nonDerivative · entry 2 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,845 F2 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:04 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 158,000 | $0.00 Strike: $15.31 | $0.00 |
DisclosureSEC source: 0001193125-26-002385 · ownership.xml · derivative · entry 3 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock · 158,000 shares Expires 2036-01-01 F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:04 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantCommon Stock | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-002385 · ownership.xml · nonDerivative · entry 1 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,000 F1 · price: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 161,000 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0000950170-25-002099 · ownership.xml · derivative · entry 2 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,000 Underlying: Common Stock · 161,000 shares Expires 2035-01-01 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantCommon Stock | 36,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002099 · ownership.xml · nonDerivative · entry 1 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 F1 · shares: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. F1 · price: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:10 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0000950170-24-069308 · ownership.xml · derivative · entry 1 Townson Sharon · CIK 0001855689 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-03 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:31 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 78,550 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-23-000952 · doc4.xml · derivative · entry 1 Townson Sharon · CIK 0001855689 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,550 Underlying: Common Stock · 78,550 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:46 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0000899243-22-008705 · doc4.xml · derivative · entry 1 Townson Sharon · CIK 0001855689 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.